highly qualified team

About HCRN

Hoosier Cancer Research Network (HCRN) is an independent nonprofit contract research organization that specializes in early phase multi-center, investigator-initiated oncology clinical trials. Our studies are conducted through a nationwide network of more than 100 academic and community sites.

Our highly qualified team provides comprehensive study management including budgeting, contracting, LOI submission, study design, regulatory and IND support, custom EDC development and validation, safety reporting, monitoring, site management, correlative management, data management, and support for publication.

Founded in 1984

Our Story

Hoosier Cancer Research Network, formerly known as Hoosier Oncology Group, was founded in 1984 by a small group of community-based oncologists and faculty members at the Indiana University Cancer Center. Our founders had a vision to bring academic and community physicians together to develop cancer trials tailored to community needs.

Our Mission

Hoosier Cancer Research Network’s mission is to form unparalleled relationships between academic, community, pharmaceutical, and biotech collaborators with the goal of advancing cancer research, education, and patient advocacy.

Academic

Pharmaceutical

Community

Advocacy

250

Clinical Trials

10k

Subjects

350

Publications

100

Academic and Community Sites

Our Impact

Since its founding, Hoosier Cancer Research Network has conducted more than 250 clinical trials in a variety of cancer types, enrolling 10,000+ subjects and producing more than 350 publications. During this time, the HCRN network has grown steadily and now consists of more than 100 academic and community sites across the United States. Hoosier Cancer Research Network’s reputation as a full-service clinical research organization has resulted in key partnerships.

Our Team

Board & Staff

Our experienced staff collaborates with investigators, member institutions, and funders to open trials, complete accrual, and publish results efficiently and cost effectively.

Year in Review

Annual Report

Learn more about HCRN’s recent accomplishments and collaborations in our latest annual report.

Awards

Terry Hoeppner Patient Advocacy Award

Terry Hoeppner, beloved Indiana University football coach, lost his battle with brain cancer in 2007. Coach Hep was known for his “never quit” attitude and determination to face challenges head-on. To honor his memory, his wife, Jane Hoeppner, created the Terry Hoeppner Patient Advocacy Award. The award honors individuals who embody Coach Hep’s spirit and determination to champion their cause.

Sandra Turner Excellence in Clinical Research Award

The Sandra Turner Excellence in Clinical Research Award was established in 2002 by Dr. William B. Fisher through the George and Sarah Jane Fisher Fund to honor the memory of Sandra Turner, the first executive director of Hoosier Cancer Research Network. Each year the organization selects individuals for the award who exemplify the qualities Sandra possessed and respected in others, such as sustained professional commitment, contribution to the progress of oncology care, and the unflinching touch of compassion.

George and Sarah Jane Fisher Young Investigator Award

In 2011, Dr. William B. Fisher and others generously established a new award through the George and Sarah Jane Fisher Fund to challenge the next generation of cancer researchers. The George and Sarah Jane Fisher Young Investigator Award honors Indiana University oncology fellows and faculty members who have made significant contributions to clinical or basic science research.

Danny Danielson Translational Innovation Award

In 2013, Donald C. “Danny” Danielson established the Danny Danielson Translational Innovation Award, granted by the Walther Cancer Foundation. The award, given twice each year, honored investigators working in partnership with Hoosier Cancer Research Network to support the correlative components of clinical trial protocols when financial support is not otherwise available. The correlatives under investigation must have a future clinical application, such as development of new treatment strategies or identification of patient subsets for specific treatment therapies, and/or provide hypotheses for future clinical trials.